SUSTOL (granisetron)
OFFICE ADMINISTRATION
FDA Approved indication:
- Indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomitting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
Prior authorization criteria:
- Patient is at least 18 years of age, AND
- Patient is receiving moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy
Dosing:
- Intended for administration by a healthcare provider
- 10 mg administered as a single subcutaneous injection at least 30 minutes before the satart of emetogenic chemotherapy on Day 1
- Administer Sustol in combination with dexamethasone at least 30 minutes before the initiation of MEC or AC combination chemotherapy
- Do not administer more frequently than once every 7 days
- Use of Sustol with successive emetogenic chemotherapy cycles for more than 6 months is not recommended
- In patients with moderate renal impairment (CLcr 30-59 mL/min), administer Sustol not more frequently than once every 14 days
- Avoid Sustol in patients with severe renal impairment (CLcr < 30 mL/min)
Approval:
- 6 months